Citigroup’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $754K | Buy |
39,278
+8,333
| +27% | +$166K | ﹤0.01% | 3293 |
|
|
2025
Q4 | $511K | Buy |
30,945
+16,009
| +107% | +$270K | ﹤0.01% | 3561 |
|
|
2025
Q3 | $217K | Sell |
14,936
-61,379
| -80% | -$882K | ﹤0.01% | 3955 |
|
|
2025
Q2 | $1.07M | Sell |
76,315
-117,689
| -61% | -$1.66M | ﹤0.01% | 3154 |
|
|
2025
Q1 | $2.64M | Buy |
194,004
+27,298
| +16% | +$523K | ﹤0.01% | 2453 |
|
|
2024
Q4 | $3.4M | Buy |
166,706
+71,992
| +76% | +$1.84M | ﹤0.01% | 2344 |
|
|
2024
Q3 | $2.76M | Buy |
94,714
+50,163
| +113% | +$1.24M | ﹤0.01% | 2390 |
|
|
2024
Q2 | $1.03M | Sell |
44,551
-337,865
| -88% | -$6.49M | ﹤0.01% | 2898 |
|
|
2024
Q1 | $7.85M | Buy |
382,416
+241,140
| +171% | +$4.53M | 0.01% | 1407 |
|
|
2023
Q4 | $3.03M | Buy |
141,276
+2,967
| +2% | +$58.8K | ﹤0.01% | 1932 |
|
|
2023
Q3 | $2.85M | Buy |
138,309
+30,282
| +28% | +$768K | ﹤0.01% | 1759 |
|
|
2023
Q2 | $3.19M | Sell |
108,027
-100,313
| -48% | -$2.82M | ﹤0.01% | 1808 |
|
|
2023
Q1 | $4.8M | Buy |
208,340
+80,220
| +63% | +$2.21M | ﹤0.01% | 1526 |
|
|
2022
Q4 | $3.56M | Sell |
128,120
-64,522
| -33% | -$1.92M | ﹤0.01% | 1666 |
|
|
2022
Q3 | $5.91M | Buy |
192,642
+80,828
| +72% | +$2.63M | ﹤0.01% | 1459 |
|
|
2022
Q2 | $3.29M | Buy |
111,814
+76,430
| +216% | +$2M | ﹤0.01% | 1768 |
|
|
2022
Q1 | $1.14M | Sell |
35,384
-84,997
| -71% | -$2.92M | ﹤0.01% | 2845 |
|
|
2021
Q4 | $5.37M | Buy |
120,381
+11,356
| +10% | +$538K | ﹤0.01% | 1775 |
|
|
2021
Q3 | $5.5M | Buy |
109,025
+43,778
| +67% | +$2.47M | ﹤0.01% | 1756 |
|
|
2021
Q2 | $5.12M | Sell |
65,247
-4,527
| -6% | -$280K | ﹤0.01% | 1874 |
|
|
2021
Q1 | $3.98M | Buy |
69,774
+52,179
| +297% | +$3.49M | ﹤0.01% | 1955 |
|
|
2020
Q4 | $1.47M | Buy |
17,595
+10,651
| +153% | +$644K | ﹤0.01% | 3147 |
|
|
2020
Q3 | $249K | Sell |
6,944
-42,920
| -86% | -$1.29M | ﹤0.01% | 4450 |
|
|
2020
Q2 | $1.21M | Buy |
49,864
+12,000
| +32% | +$282K | ﹤0.01% | 3359 |
|
|
2020
Q1 | $663K | Buy |
37,864
+20,342
| +116% | +$424K | ﹤0.01% | 3603 |
|
|
2019
Q4 | $305K | Sell |
17,522
-60,995
| -78% | -$1.02M | ﹤0.01% | 4835 |
|
|
2019
Q3 | $1.2M | Buy |
78,517
+14,034
| +22% | +$268K | ﹤0.01% | 3428 |
|
|
2019
Q2 | $1.34M | Buy |
64,483
+52,480
| +437% | +$1.18M | ﹤0.01% | 3288 |
|
|
2019
Q1 | $279K | Sell |
12,003
-77,311
| -87% | -$1.62M | ﹤0.01% | 4770 |
|
|
2018
Q4 | $1.84M | Buy |
89,314
+76,458
| +595% | +$1.39M | ﹤0.01% | 2753 |
|
|
2018
Q3 | $279K | Buy |
12,856
+10,429
| +430% | +$173K | ﹤0.01% | 4904 |
|
|
2018
Q2 | $37K | Buy |
2,427
+132
| +6% | +$2.49K | ﹤0.01% | 6506 |
|
|
2018
Q1 | $45K | Buy |
+2,295
| New | +$47.2K | ﹤0.01% | 6231 |
|
Other funds holding DNLI
VCM
VPM
Citigroup's DNLI Position: Q1 2026 in Review
Citigroup increased its Denali Therapeutics (DNLI) stake by 27% in Q1 2026, buying an estimated $166K and bringing the position to 39,278 shares worth $754K. The position accounts for ﹤0.01% of the portfolio, ranked #3293.
Citigroup first reported a position in DNLI in Q1 2018 and has held it in 33 quarters since. The position peaked at $7.85M in Q1 2024. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.
- Citigroup held 39,278 shares of Denali Therapeutics worth $754K as of Q1 2026.
- Citigroup bought 8,333 Denali Therapeutics shares in Q1 2026, an estimated $166K.
- Denali Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #3293 holding.
- Citigroup first reported a position in Denali Therapeutics in Q1 2018 and has held it in 33 quarters since.
- Citigroup's Denali Therapeutics position peaked at $7.85M in Q1 2024.
- 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.